Here are the 10-K annual reports from Editas Medicine, Inc. (EDIT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine, Inc. provides an overview of its business and strategy as a CRISPR-based gene editing company focused on in vivo genomic medicines. The company’s lead development candidate, EDIT-401, is designed as a one-time therapy to upregulate the LDL receptor and significantly lower LDL cholesterol in patients with hyperlipidemia, including heterozygous familial hypercholesterolemia.
Editas is building a “plug ’n play” lipid nanoparticle platform to deliver CRISPR medicines to the liver, hematopoietic stem cells, and other tissues, and is shifting resources from its former ex vivo sickle cell program to in vivo approaches. The company also outlines multiple collaborations and licensing deals, including a non‑exclusive Cas9 license to Vertex for sickle cell disease and beta thalassemia and a royalty‑monetization agreement with DRI Healthcare Trust, alongside a broad patent estate licensed from Broad, Harvard, and others covering Cas9 and Cas12a technologies.